Core B: PDX/Biospecimen Core

PDX/Biospecimen核心B为P01项目提供部分基础设施支持。它 专为满足这些项目的需求而设计，并作为 合作努力。核心B将提供一个组织良好和标准化的系统 标本收集、储存、分发和相关的临床/研究信息 传播。在病理分析中将有一致性和质量保证 组织标本。样本来自我们的存储库，我们的LuCaP前列腺癌PDX和临床 样本，特别是来自我们快速尸检计划的样本(例如前列腺癌骨骼 转移)已经并将继续分发给其他前列腺癌研究人员 在国家和国际基础上。核心B的具体目标是：1)维护和分发 患者来源的前列腺癌异种移植，2)收集和分发临床生物制剂(即 组织，包括手术和快速尸检程序中的组织，血清、血浆和尿液)， 加工、质量控制、储存、配送和数据库录入，3)建立和维护 标本质量和核心B服务效率计划，4)提供专门的病理学 和实验室服务，包括组织微阵列的生产、解释 泌尿外科病理学家的免疫组织学，标本衍生品的制作和PSA的执行 用于研究的免疫分析，5)从少数族裔获取样本的行政程序， 优先分发样本，确保患者保密并遵守IRB 要求，并不断完善质量控制措施。

The PDX/Biospecimen Core B provides part of the infrastructure support for the P01 Projects. It has been designed to meet the needs of these projects and serve as a stand-alone resource for collaborative efforts. The Core B will provide a well-organized and standardized system of specimen collection, storage, distribution and related clinical/research information dissemination. There will be consistency and quality assurance in the pathological analysis of tissue specimens. Specimens from our repository, our LuCaP prostate cancer PDXs and clinical specimens, particularly those from our rapid autopsy program (e.g. prostate cancer bone metastases) have been and will continue to be distributed to other prostate cancer investigators on a national and international basis. The Core B Specific Aims are: 1) Maintain and Distribute Patient-Derived Prostate Cancer Xenografts, 2) Collect and Distribute Clinical Biopecimens (i.e. tissues, including those from surgery and the rapid autopsy program, serum, plasma and urine), processing, quality control, storage, distribution and database entry, 3) Establish and Maintain Specimen Quality and Core B Service Efficiency Programs, 4) Provide Specialized Pathology and Laboratory Services, including production of tissue microarrays, interpretation of immunohistology by urologic pathologists, production of specimen derivatives and perform PSA immunoassays for research, 5) Administrative Program to obtain samples from minorities, prioritize the distribution of specimens, ensure patient confidentiality and compliance with IRB requirements, and continually improve quality control measures.